Arecor Therapeutics plc
Research Arecor Therapeutics plc (AREC.L) on Bullrun: market cap GBX 2.74B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAREC.L
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 2.74B
- Financial periodFY2025
- RevenueGBP 1.71M
- Revenue growth4.3%
- Net incomeGBP 664.00K
- Free cash flow-GBP 2.46M
- Gross margin73.9%
Valuation Snapshot
latest market cap is GBX 2.74B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 1.71M | GBP 664.00K | -GBP 2.46M | 73.9% | 0.02 | GBP 3.00M | GBP 98.00K | GBP 6.45M |
| FY2024 | GBP 1.64M | -GBP 10.24M | -GBP 9.34M | 55.9% | -0.31 | GBP 3.24M | GBP 232.00K | GBP 5.35M |
| FY2023 | GBP 4.57M | -GBP 8.55M | -GBP 5.99M | 27.4% | 0 | GBP 5.09M | GBP 338.00K | GBP 9.53M |
| FY2022 | GBP 2.40M | -GBP 9.26M | -GBP 11.13M | n/a | -0.32 | GBP 4.77M | GBP 288.00K | GBP 17.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | GBX 2.74B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Arecor Therapeutics plc
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arecor Therapeutics plc's market cap?
Arecor Therapeutics plc's market capitalization is GBX 2.74B.
What does Arecor Therapeutics plc do?
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.